Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Emcure Pharmaceuticals IPO is 45. Their analysis recommends May Subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 45 | May Subscribe |
[Dilip Davda] The company is one of the leading pharma company having niche products and serving global markets. It marked growth in its top lines, but bottom line posted declining trends due to higher interest and depreciation costs. Based on FY24 earnings, the issue appears fully priced. Reduction in debt post IPO will improved its bottom line commensurately. Investors may park funds for the medium to longer term. Read detail review...
Emcure Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 31, 2024)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | 27.54 | 27.54 | 163.22 | 21.27 | Consolidated | ||
| Dr. Reddy's Laboratories Limited | 335.22 | 335.59 | 1,693.75 | 17.93 | 19.74 | 3.54 | Consolidated |
| Cipla Ltd. | 51.05 | 51.01 | 330.78 | 30.10 | 15.43 | 4.64 | Consolidated |
| Alkem Laboratories Ltd | 150.19 | 150.19 | 862.46 | 33.86 | 17.41 | 5.90 | Consolidated |
| Torrent Pharmaceuticals Ltd. | 48.94 | 48.94 | 202.57 | 57.74 | 24.15 | 13.95 | Consolidated |
| Mankind Pharma Limited | 47.75 | 47.68 | 233.73 | 45.30 | 20.43 | 9.24 | Consolidated |
| Abbott India Ltd. | 565.28 | 565.28 | 1,740.71 | 47.43 | 32.48 | 15.40 | Consolidated |
| J. B. Chemicals & Pharmaceuticals Limited | 35.66 | 34.85 | 188.37 | 50.49 | 18.90 | 9.34 | Consolidated |
The financial information for Emcure Pharma is based on the Restated Consolidated Financial Statements as of and for the financial year ended March 31, 2024. The financial information for listed industry peers mentioned above, sourced from the audited financial statements of the respective companies for the financial year ended March 31, 2024, is on a consolidated basis (except for Abbott India Limited, where financial information is available only on a standalone basis) and is submitted to the Stock Exchanges.
Notes:
Emcure Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Emcure Pharmaceuticals Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP